Medinice

Medinice CROIC

The Cash Return on Invested Capital (CROIC) of Medinice (ICE.WA) as of Oct 27, 2026 is -13.17 %. In the previous year, Cash Return on Invested Capital (CROIC) was -4.50 % — a change of 192.94% (lower).

CROIC

-13.17 %

YoY

192.94%

Last updated:

Cash Return on Invested Capital (CROIC) of Medinice is 2025 -13.17 % . Cash Return on Invested Capital (CROIC) of Medinice was 2024 -4.50 % . It decreases by 192.94% lower compared to the previous year.

The Medinice CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-63.08 PLN
Jan 1, 2019
-69.19 PLN
Jan 1, 2020
-35.97 PLN
Jan 1, 2021
-14.60 PLN
Jan 1, 2022
-16.72 PLN
Jan 1, 2023
-29.46 PLN
Jan 1, 2024
-4.50 PLN
Jan 1, 2025
-13.17 PLN
The Medinice CROIC history
YEARCROICYoY
-13.17 %+192.94%
-4.50 %-84.74%
-29.46 %+76.24%
-16.72 %+14.52%
-14.60 %-59.42%
-35.97 %-48.01%
-69.19 %+9.68%
-63.08 %+23.90%
-50.91 %-71.20%
-176.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medinice Stock analysis

What does Medinice do? Medinice SA generates revenue through the commercialization of medical device solutions, primarily focusing on cardiological and cardiosurgical products. The company's portfolio includes CathAIO, Cryoapplicator, Med-IConsole, Minimax, and Pacepress, which are sold globally via licensing agreements. These products target healthcare providers and medical device manufacturers seeking minimally invasive cardiology solutions. The firm collaborates with research centers in Poland and Europe to develop and commercialize inventions from its co-founders and acquired projects, emphasizing safe and minimally invasive medical technologies. Medinice SA's business model revolves around licensing its proprietary technologies to international partners for the production of medical devices. The company leverages its global potential projects to secure worldwide distribution agreements, ensuring revenue streams from multiple markets. By specializing in cardiology and cardio surgery, Medinice SA positions itself as a provider of innovative solutions for healthcare systems seeking advanced, minimally invasive procedures. The firm's revenue is derived from licensing fees and sales of its medical device solutions, with a focus on cardiological and cardiosurgical applications. Its products, such as CathAIO and Cryoapplicator, are designed to meet global demand for safe and minimally invasive treatments. Medinice SA's strategy involves partnering with research centers in Poland and Europe to enhance its portfolio, ensuring continuous innovation and market relevance in the medical device sector. Medinice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinice stock

Cash Return on Invested Capital (CROIC) of Medinice is -13.17 % in 2025.

Cash Return on Invested Capital (CROIC) of Medinice changed from -4.50 % to -13.17 %, representing a 192.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Medinice since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Medinice with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medinice

All Key Metrics — Medinice